NCT03739424

Brief Summary

This project is the first egg feeding randomized controlled trial (RCT) in children. The goal of this RCT is to determine if eating formulated whole egg products for 9 months improves bone health and cognitive function in children ages 9-13 years more than children consuming products made of milk powder or gelatin.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
182

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Apr 2018

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 28, 2018

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

November 6, 2018

Completed
7 days until next milestone

First Posted

Study publicly available on registry

November 13, 2018

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 11, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 11, 2020

Completed
Last Updated

November 3, 2020

Status Verified

November 1, 2020

Enrollment Period

2.2 years

First QC Date

November 6, 2018

Last Update Submit

November 2, 2020

Conditions

Keywords

BoneCognitionEggProtein

Outcome Measures

Primary Outcomes (3)

  • Bone Outcomes

    Three-dimensional cortical and trabecular bone geometry measures will be assessed via pQCT at the tibia and radius. Outcome measures from the pQCT will include cortical and trabecular bone mineral density, cortical bone mineral area, total area, periosteal circumference, endosteal circumference, strength strain index, and bone strain index. DXA will be used to assess two-dimensional bone measurements at the lumbar spine, non-dominant hip, forearm, and total body.

    Assess changes in bone outcomes from baseline to 9 months

  • Body Composition

    Body composition measures (i.e., total body fat mass, fat-free soft tissue mass, and percent body fat) will be assessed by DXA.

    Measure changes in body composition from baseline to 4.5 months and 9 months.

  • Cognitive Health

    Cognitive health will be measured using the National Institute of Health's Toolbox. This toolbox for which validity evidence and national norms for children have been provided (Tulsky et al., 2013; Akshoomoff et al., 2014; Weintraub et al., 2013; Zelazo et al., 2013), will measure six cognitive domains: Executive Function, Episodic Memory, Working Memory, Attention, Language Ability, and Processing Speed.

    Changes in cognitive function will be assessed from baseline to 4.5 and 9 months

Secondary Outcomes (9)

  • Serum Lipids

    Serum samples will be collected at baseline, 4.5 months and 9 months

  • Insulin

    Serum samples will be collected at baseline, 4.5 months and 9 months

  • Insulin like growth factor 1

    Serum samples will be collected at baseline, 4.5 months and 9 months

  • Vascular endothelial growth factor

    Serum samples will be collected at baseline, 4.5 months and 9 months

  • C-reactive protein

    Serum samples will be collected at baseline, 4.5 months and 9 months

  • +4 more secondary outcomes

Study Arms (3)

Whole egg powder arm

EXPERIMENTAL

The whole egg powder arm will be part of our food product intervention. Food products created using whole egg powder will be provided and consumed 10x/week for 9 months. Each food item will contain the equivalent of one whole egg.

Other: Whole egg powder

Whole milk powder arm

ACTIVE COMPARATOR

The whole milk powder arm will be part of our food product intervention. Food products created using whole milk powder will be provided and consumed 10x/week for 9 months. These items will have the equivalent amount of protein as the whole egg group. They will be isocaloric in nature.

Other: Whole milk powder

Gelatin arm

PLACEBO COMPARATOR

The gelatin food products will be a part of our food product intervention. Food products created using gelatin will be provided and consumed 10x/week for 9 months. These items will be isocaloric in nature to the other treatment arms but will not contain additional protein.

Other: Gelatin food product

Interventions

Participants will receive waffles, pancakes, brownies, ice cream and mac and cheese made with whole egg powder. The food projects were developed specifically for this study by the University of Georgia's Food Product Innovation and Commercialization Center and consumer tested by children within the study age range prior to intervention enrollment.

Whole egg powder arm

Participants will receive waffles, pancakes, brownies, ice cream and mac and cheese made with whole milk powder. The food projects were developed specifically for this study by the University of Georgia's Food Product Innovation and Commercialization Center and consumer tested by children within the study age range prior to intervention enrollment.

Whole milk powder arm

Participants will receive waffles, pancakes, brownies, ice cream and mac and cheese made with gelatin. The food projects were developed specifically for this study by the University of Georgia's Food Product Innovation and Commercialization Center and consumer tested by children within the study age range prior to intervention enrollment.

Gelatin arm

Eligibility Criteria

Age9 Years - 13 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Apparently healthy and well-nourished
  • White, Black or Hispanic
  • Males and females between the chronological ages of 9-13 years
  • Sexual maturation rating, as measured by Tanner, at stages 2/3.
  • Must be willing to provide a blood sample
  • Not allergic to egg or egg products, milk or milk products, or gelatin

You may not qualify if:

  • Achievement of menarche (females)
  • Sexual maturation rating, as measured by Tanner, at stages 4/5
  • Known bone disease or disease know to influence bone metabolism (e.g., cerebral palsy, intestinal malabsorption, juvenile rheumatoid arthritis)
  • Known growth disorders
  • The use of medications that may influence bone metabolism (e.g., corticosteroids, attention-deficit/hyperactivity disorder medications)
  • Allergic to egg or egg products, milk or milk products, or gelatin

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Georgia

Athens, Georgia, 30606, United States

Location

Related Publications (5)

  • Tulsky DS, Carlozzi NE, Chevalier N, Espy KA, Beaumont JL, Mungas D. V. NIH Toolbox Cognition Battery (CB): measuring working memory. Monogr Soc Res Child Dev. 2013 Aug;78(4):70-87. doi: 10.1111/mono.12035.

  • Akshoomoff N, Newman E, Thompson WK, McCabe C, Bloss CS, Chang L, Amaral DG, Casey BJ, Ernst TM, Frazier JA, Gruen JR, Kaufmann WE, Kenet T, Kennedy DN, Libiger O, Mostofsky S, Murray SS, Sowell ER, Schork N, Dale AM, Jernigan TL. The NIH Toolbox Cognition Battery: results from a large normative developmental sample (PING). Neuropsychology. 2014 Jan;28(1):1-10. doi: 10.1037/neu0000001. Epub 2013 Nov 11.

  • Weintraub S, Dikmen SS, Heaton RK, Tulsky DS, Zelazo PD, Bauer PJ, Carlozzi NE, Slotkin J, Blitz D, Wallner-Allen K, Fox NA, Beaumont JL, Mungas D, Nowinski CJ, Richler J, Deocampo JA, Anderson JE, Manly JJ, Borosh B, Havlik R, Conway K, Edwards E, Freund L, King JW, Moy C, Witt E, Gershon RC. Cognition assessment using the NIH Toolbox. Neurology. 2013 Mar 12;80(11 Suppl 3):S54-64. doi: 10.1212/WNL.0b013e3182872ded.

  • Zelazo PD, Anderson JE, Richler J, Wallner-Allen K, Beaumont JL, Weintraub S. II. NIH Toolbox Cognition Battery (CB): measuring executive function and attention. Monogr Soc Res Child Dev. 2013 Aug;78(4):16-33. doi: 10.1111/mono.12032.

  • O'Connor PJ, Chen X, Coheley LM, Yu M, Laing EM, Oshri A, Marand A, Lance J, Kealey K, Lewis RD. The effects of 9 months of formulated whole-egg or milk powder food products as meal or snack replacements on executive function in preadolescents: A randomized, placebo-controlled trial. Am J Clin Nutr. 2022 Dec 19;116(6):1663-1671. doi: 10.1093/ajcn/nqac281.

Study Officials

  • Richard D Lewis, PhD

    University of Georgia

    PRINCIPAL INVESTIGATOR
  • Nicole J Crenshaw

    University of Georgia

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
UGA Foundation Professor in Family and Consumer Sciences

Study Record Dates

First Submitted

November 6, 2018

First Posted

November 13, 2018

Study Start

April 28, 2018

Primary Completion

July 11, 2020

Study Completion

July 11, 2020

Last Updated

November 3, 2020

Record last verified: 2020-11

Locations